===
Lonza Group AG / Key word(s): Personnel
Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
2024-07-01 / 07:00 CET/CEST
. Wolfgang Wienand commences his tenure as Chief Executive Officer of Lonza Group
. Albert M. Baehny will retire from Lonza Group following a transition period
Basel, Switzerland, 1 July 2024 - Wolfgang Wienand joins Lonza Group today as Chief Executive Officer (CEO). Wolfgang
succeeds Albert M. Baehny, who took on the role of CEO ad interim in October 2023 and was Chairman of the Board of
Directors of Lonza from 2018 to May 2024. Albert will work with Wolfgang to ensure a smooth leadership handover before
he retires from Lonza this summer.
Jean-Marc Huët, Chairman of the Board of Directors, Lonza, commented: "On behalf of the Board, I extend a warm welcome
to Wolfgang as he joins Lonza. Wolfgang brings with him a wealth of CDMO experience, combined with deep strategic and
scientific expertise. As Wolfgang joins, we look forward to an era of stable and structured growth under his
leadership."
Wolfgang Wienand, Chief Executive Officer, Lonza, commented: "Having worked in the CDMO industry for almost two
decades, I always had great respect for Lonza's ability to transform and grow at pace. It is a privilege to join this
remarkable company as CEO. As I commence my journey with Lonza, we are embarking on a quest to meet and exceed the
needs of our customers and their patients. I am greatly looking forward to working with the team to build on our strong
foundations and create a strategy for us to deliver continued growth and reach our full potential."
Since 2019, Wolfgang has held the role of CEO at Swiss CDMO, Siegfried. Wolfgang previously served as Chief Scientific
Officer and then as Chief Strategy Officer in Siegfried's executive leadership team. Prior to joining Siegfried in
2010, Wolfgang held a series of positions with increasing seniority at the German specialty chemicals company Evonik
Industries.
About Lonza
Lonza is one of the world's largest healthcare manufacturing organizations. Working across five continents, our global
community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments
to market. United by our vision to bring any therapy to life, we support our customers with a combination of
technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work
enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit
from life-saving and life-enhancing treatments.
Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell
& Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 6.7 billion with a CORE EBITDA of CHF 2.0
billion in Full-Year 2023. Find out more at www.lonza.com
Follow @Lonza on LinkedIn
Follow @LonzaGroup on X
Lonza Contact Details
Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com
Daniel Buchta
Investor Relations
Lonza Group Ltd
Tel +41 61 316 2985
daniel.buchta@lonza.com
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary
listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's
continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on
current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these
expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks
and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the
forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise
required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news
release.
All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners
and are used only for informational purposes.
Privacy Policy link

To immediately delete all the data  
End of Media Release  
Language:     English 
Company:      Lonza Group AG 

Münchensteinerstrasse 38
4052 Basel
Switzerland

Phone:        +4161 316 81 11 
Internet:     www.lonza.com 
ISIN:         CH0013841017 
Valor:        1384101 
Listed:       SIX Swiss Exchange 
EQS News ID:  1935935 

End of News EQS News Service
===
1935935 2024-07-01 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1935935&application_name=news&site_id=dow_jones%7e%7e%7e43f1f857-252a-44a4-bbde-f4a32f6a5492

END) Dow Jones Newswires

July 01, 2024 01:01 ET (05:01 GMT)